Description

GHRP-6 & CJC-1295 Mix

5mg ghrp-6 & 5mg cjc-1295 in each vial

Description

GHRP-6 (Growth Hormone Releasing Peptide —6) is a hexapeptide with a chain

composed of 6 amino acids. It is one of several synthetic met-enkephalin analogs

that include unnatural D-amino acids that were developed for their growth hormone

releasing activity and are called growth hormone secretagogues. GHRP-6 is true

HGH secretagogue.

This growth hormone releasing peptide is distinct from GHRH and do not act at the

GHRH receptor, but instead acts al the growth hormone secretagogue receptor, now

renamed as the ghrelin receptor.

CJC-1295 is a tetrasubstituted 30-amino acid peptide hormone, primarily

functioning as a growth hormone releasing hormone (GHRH) analog. It has D-Ala,

Gin, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively.

GHRP-6 & CJC-1295 are sterile, non-pyrogenic, white lyophilized powder intended

for subcutaneous or intramuscular injection, after reconstitution with sterile Water

for Injection.

Mechanism of Action

GHRP-6 is not an active fragment of growth hormone releasing hormone (GHRH).

Which means it stimulates the body’s own secretion of HGH. Human Growth

hormone has been shown in studies to promote lean body mass and reduce

adiposity (fat). This growth hormone releasing peptide is distinct from GHRH and do

not act the GHRH receptor, but instead acts al the growth hormone secretagogue

receptor, now renamed as the gh-relin receptor.

GHRP-6’s special sequence is considered to provide a signal to the body to begin

secreting Growth Hormone (GH) release while also blocking Somatostatin, a

hormone that inhibits Growth Hormone release. Research Studies have shown that

GHRP-6 stimulation of Growth Hormone has host of beneficial effects such as

decreased body fat, increased muscle, and increased strength and stamina so

maximizing the production and secretion can be great addition to improved animal

physical shape. Increased amounts of Growth Hormone then can cause the liver to

secrete the hormone IGF-1 which has also been implicated in improving the animal

body’s ability to burn fat and build muscle. Clinical cases have shown that the use of

GHRP-6 was associated with increased muscle mass and a reduction of body fat.

GHRP-6 has been one of the most thoroughly studied and is believed to be acting

naturally on both pituitary and hypothalamic sites (Fairhall et al, 1995). This has

been demonstrated in the primary pituitary cells of rats in a time-dependent and

dose-dependent manner. In another study of Fairhall et al. (1995), they concluded

that the major target of the GHRP-6 in vivo is the hypothalamus after observing that

the GH(Growth Hormone) release induced by the central GHRP-6 administration is

guinea pigs was inhibited by the central action of somatostatin. Furthermore, an

inhibition by somatostatin with the activated GRF neurons (GRF=Growth Hormone

Releasing Factor), induced by GHRP-6, was observed via receptors known to be

located on or near the GRF themselves. However, it was also observed that GHRP-6

had no effect on the intracellular cAMP levels unlike that of GHRP-2. This particular

experiment further indicated that GHRP-6 is effectively stimulating GH release from

somatotrophs through different receptors, the mechanisms of which are not yet

known (Chan et al. 1989).

However, some researchers suggest that action and efficiency of growth hormone is

dependent on the physical condition of the experimental unit. In humans for

example, GH secretion decreased with obesity. This is contrary in the case of the

GHRP-6 which showed increased (almost twice that of GHRP) GH responses when

administered in obese patients (Cordido et al. 1993). Though obesity has shown

affecting the efficiency of the hormone, it was also suggested that GHRP-6’s effects,

at least at the dose-dependent manners, were found to be sex-and age-independent

without being affected by the adrenergic pathways using the a2 adrenergic

receptors (Penalva et al. 2008).

CJC-1295 is a long acting growth hormone releasing hormone (GHRH) analog.

GHRH, also known as growth hormone releasing factor or somatocrinin, which is

produced by the arcuate nucleus in the hypothalamus. It stimulates secretion of

growth hormone from the pituitary gland and is released in a pulsatile manner to

ultimately stimulate pulsatile release of growth hormone. The result is an increasing

level of both HGH (Human Growth Hormone) and IGF-1 (Insulin-like Growth

Factor).

One very important advantage of CJC-1295 is that because of its half life, which is

between 10-30 minutes, the user can control the levels of HGH and IGF-1. That

means you can have high levels, when you think its best for results.